Financial comparisons GC Genome Corporation
Stocks
A340450
KR7340450006
Healthcare Facilities & Services
|
End-of-day quote
Korea S.E.
23/09/2026
|
5-day change | 1st Jan Change | ||
| 8,180.00 KRW | +12.21% |
|
+16.86% | +19.94% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
 | 2.31B | -9.03% | -13.44% | -14.32% | -10.26% | 3.74x | |
| 13.95B | 6.28% | 14.35% | 16.52% | 7.49% | 2.1x | |
| 7.58B | 5.55% | 9.24% | 7.3% | 3.78% | 1.63x | |
| 2.04B | -0.91% | 3.04% | - | - | 1.07x | |
| 295M | 18.27% | 22.47% | 21.57% | 17.22% | -1.7x | |
| 428M | -4.92% | 9.66% | - | - | - | |
| 727M | -14.85% | -15.93% | 1.71% | - | - | |
| 1.51B | 7.39% | 14.73% | 11.91% | 4.66% | 1.46x | |
| 862M | -2.87% | -2.15% | -2.51% | -1.73% | -4.19x | |
| 1.44B | 0.44% | 2.79% | 0.68% | 0.29% | 0.58x | |
| 86.83M | 21.24% | 30.1% | 19.7% | 12.44% | -0.83x | |
| 1.56B | 2.76% | 1.93% | 5% | 1.04% | 1.01x | |
| 316M | 7.56% | 8.76% | 6.49% | 4.36% | - | |
| 607M | -37.19% | -19.34% | -17.14% | -10.92% | 0.19x | |
| 88.42M | 19.67% | 24.54% | 29.61% | - | - | |
| 945M | 5.16% | 6.94% | 6% | 4.23% | - | |
| Average | 2.17B | 1.53% | 6.1% | 6.61% | 2.72% | 0.46x | |
| Weighted average by Cap. | 4.77B | -2.49% | -1.61% | -2.02% | -2.9% | 2.55x |
- Stock Market
- Stocks
- A340450 Stock
- Sector GC Genome Corporation
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
